ARANZ Medical   Report issue

For profit Phase 2 Phase 3
Founded: Christchurch New Zealand (1995)

Organization Overview

First Clinical Trial
2011
NCT01421966
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

leukocytes (1 trial)

Drugs in Phase 2 Trials (1)

vf001-dp (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiovascular Diseases (Phase 2)

Leg Ulcer (Phase 2)

Pathologic Processes (Phase 2)

Skin Diseases (Phase 2)

Skin Ulcer (Phase 2)

Ulcer (Phase 3)

Varicose Ulcer (Phase 2)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2